AST and ALT> 3-5x ULN at visit and bilirubin> 1.5 x ULN at visit creatinine clearance rate calculated by Cockcroft-Gault formula at visit 1 <30 mL / min Confirmed previous Idiopathic pulmonary fibrosis,previous treatment with Nidanib or Pirfenidone Significant pulmonary hypertension (PAH) Cardiovascular diseases, including any of the following diseases: ① Severe hypertension within 6 months of Visit 1, uncontrollable after treatment (≥160 / 100 mmHg); ② myocardial infarction within 6 months of visit 1; ③ unstable angina within 6 months of visit 1 history of severe central nervous system (CNS) events known trials Drug allergies Patients unable to follow the trial procedures Pregnancy Breastfeeding

AST and ALT> 3-5x ULN at visit and bilirubin> 1.5 x ULN at visit creatinine clearance rate calculated by Cockcroft-Gault formula at visit 1 <30 mL / min Confirmed previous Idiopathic pulmonary fibrosis,previous treatment with Nidanib or Pirfenidone Significant pulmonary hypertension (PAH) Cardiovascular diseases, including any of the following diseases: ① Severe hypertension within 6 months of Visit 1, uncontrollable after treatment (≥160 / 100 mmHg); ② myocardial infarction within 6 months of visit 1; ③ unstable angina within 6 months of visit 1 history of severe central nervous system (CNS) events known trials Drug allergies Patients unable to follow the trial procedures Pregnancy Breastfeeding